Drugs / SCLnow 19#
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03176498 | Dec 2026 → Jun 2027 | cerebral infarction | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 1/2 | NCT03180463 | Dec 2026 → Jun 2027 | avascular necrosis | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03383081 | Oct 2018 → Jun 2026 overdue | osteoarthritis, knee | Sclnow Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCLnow 19# | “Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)” NCT03176498 ↗ |
| Known as | 19#iSCLife-CI | “Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.” NCT03176498 ↗ |
| Modality | Cell therapy | “Human Umbilical Cord Mesenchymal Stem Cell Therapy” NCT03176498 ↗ |
| Route | Intravenous | “Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)” NCT03176498 ↗ |